Chaudhary Shristy, Rana Abhilash, Bhatnagar Seema
Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.
Mini Rev Med Chem. 2025;25(8):601-627. doi: 10.2174/0113895575339660250106093738.
Metabolic reprogramming is a hallmark of cancer. Distinct and unusual metabolic aberrations occur during tumor development that lead to the growth and development of tumors. Oncogenic signaling pathways eventually converge to regulate three major metabolic pathways in tumor cells i.e., glucose, lipid, and amino acid metabolism. Therefore, identifying and targeting the metabolic nodes of cancer cells can be a promising intervention and therapeutic strategy for patients with malignancies. The long road of new drug discovery for cancer therapy has necessitated relooking alternative strategies such as drug repurposing. Advanced genomic and proteomic technologies for the assessment of cancer-specific biological pathways have led to the discovery of new drug targets, which provide excellent opportunities for drug repurposing. The development of effective, safe, cheaper, and readily available anticancer agents is the need of the hour, and drug repurposing has the potential to break the current drug shortage bottleneck. This review will accordingly cover various metabolic pathways that are aberrant in cancer, and strategies for targeting metabolic reprogramming by using repurposed drugs.
代谢重编程是癌症的一个标志。在肿瘤发生发展过程中会出现独特且异常的代谢异常，这些异常导致肿瘤的生长和发展。致癌信号通路最终汇聚以调节肿瘤细胞中的三大代谢途径，即葡萄糖、脂质和氨基酸代谢。因此，识别并靶向癌细胞的代谢节点可能是针对恶性肿瘤患者的一种有前景的干预和治疗策略。癌症治疗新药研发的漫长道路使得人们有必要重新审视诸如药物重新利用等替代策略。用于评估癌症特异性生物学途径的先进基因组学和蛋白质组学技术已导致发现新的药物靶点，这为药物重新利用提供了绝佳机会。开发有效、安全、廉价且易于获得的抗癌药物是当务之急，而药物重新利用有潜力打破当前的药物短缺瓶颈。本综述将相应涵盖癌症中异常的各种代谢途径，以及使用重新利用药物靶向代谢重编程的策略。
